194 related articles for article (PubMed ID: 11454943)
1. Induction of Tmolt4 leukemia cell death by 3,3-disubstituted-6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2-4-diones: specificity for type II inosine 5'-monophasphate dehydrogenase.
Barnes BJ; Izydore RA; Eakin AE; Hall IH
J Pharmacol Exp Ther; 2001 Aug; 298(2):790-6. PubMed ID: 11454943
[TBL] [Abstract][Full Text] [Related]
2. Implications of selective type II IMP dehydrogenase (IMPDH) inhibition by the 6-ethoxycarbonyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones on tumor cell death.
Barnes BJ; Eakin AE; Izydore RA; Hall IH
Biochem Pharmacol; 2001 Jul; 62(1):91-100. PubMed ID: 11377400
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of human Molt-4 leukemia type II inosine 5'-monophosphate dehydrogenase by the 1,5-diazabicyclo[3.1.0]hexane-2,4-diones.
Barnes BJ; Eakin AE; Izydore RA; Hall IH
Biochemistry; 2000 Nov; 39(45):13641-50. PubMed ID: 11076502
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of the antitumor agents 6-benzoyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: potent inhibitors of human type II inosine 5'-monophosphate dehydrogenase.
Barnes BJ; Izydore RA; Eakin AE; Hall IH
Int J Cancer; 2001 Oct; 94(2):275-81. PubMed ID: 11668509
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the in vitro inhibition of murine and human tumor cell growth by pyrazole derivatives and a substituted azabicyclo [3.1.0] hexane-2,4-dione.
Barnes BJ; Izydore RA; Hall IH
Anticancer Res; 2001; 21(4A):2313-21. PubMed ID: 11724288
[TBL] [Abstract][Full Text] [Related]
6. Targeting of human Tmolt4 leukemic type II IMP dehydrogenase by cyclic imide related derivatives.
Hall IH; Barnes BJ; Ward ES; Wheaton JR; Shaffer KA; Cho SE; Warren AE
Arch Pharm (Weinheim); 2001 Jul; 334(7):229-34. PubMed ID: 11512273
[TBL] [Abstract][Full Text] [Related]
7. Tmolt4 leukemic type II isoform of IMP dehydrogenase as a target for 1,2,4-triazolidine-3,5-diones, 1-(1-(3-methylphenyl)ethylidineamino)-4,4-diethyl-3,5-azetidinediones, 3,5-isoxazolidinediones, and 4,4-disubstituted-3,5-pyrazolidinediones.
Hall IH; Barnes BJ; Ward ES; Wheaton JR; Warren AE; Izydore RA
Arch Pharm (Weinheim); 2001 Apr; 334(4):109-16. PubMed ID: 11382145
[TBL] [Abstract][Full Text] [Related]
8. Specific inhibition of type II inosine monophosphate dehydrogenase activity of Tmolt4 T cell human leukaemia cells by 3-methoxy and di-benzohydroxamic acids, maleic hydrazide and malonic acids.
Hall IH; Barnes BJ; Ward ES; Wheaton JR; Izydore RA
J Pharm Pharmacol; 2001 May; 53(5):749-55. PubMed ID: 11370715
[TBL] [Abstract][Full Text] [Related]
9. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
Jayaram HN; Cooney DA; Grusch M; Krupitza G
Curr Med Chem; 1999 Jul; 6(7):561-74. PubMed ID: 10390601
[TBL] [Abstract][Full Text] [Related]
10. Inosine-5'-monophosphate dehydrogenase is required for mitogenic competence of transformed pancreatic beta cells.
Metz S; Holland S; Johnson L; Espling E; Rabaglia M; Segu V; Brockenbrough JS; Tran PO
Endocrinology; 2001 Jan; 142(1):193-204. PubMed ID: 11145582
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity and mode of action of 1-(1-cyclohexenyl) and 1-unsubstituted 3,5-pyrazolidinediones in human Molt4 T cell leukemia.
Barnes BJ; Izydore RA; Hall IH
Anticancer Res; 2001; 21(3B):1857-68. PubMed ID: 11497269
[TBL] [Abstract][Full Text] [Related]
12. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Wright DG; Boosalis M; Malek K; Waraska K
Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
[TBL] [Abstract][Full Text] [Related]
13. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents.
Franchetti P; Grifantini M
Curr Med Chem; 1999 Jul; 6(7):599-614. PubMed ID: 10390603
[TBL] [Abstract][Full Text] [Related]
14. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes.
Jain J; Almquist SJ; Ford PJ; Shlyakhter D; Wang Y; Nimmesgern E; Germann UA
Biochem Pharmacol; 2004 Feb; 67(4):767-76. PubMed ID: 14757177
[TBL] [Abstract][Full Text] [Related]
15. IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine.
Vethe NT; Bremer S; Bergan S
Scand J Clin Lab Invest; 2008; 68(4):277-85. PubMed ID: 18609073
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase and differentiation induction of K562 cells among the mycophenolic acid derivatives.
Mitsuhashi S; Takenaka J; Iwamori K; Nakajima N; Ubukata M
Bioorg Med Chem; 2010 Nov; 18(22):8106-11. PubMed ID: 20934342
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N-(2,3,5-triazoyl)mycophenolic amide and mycophenolic epoxyketone as novel inhibitors of human IMPDH.
Sunohara K; Mitsuhashi S; Shigetomi K; Ubukata M
Bioorg Med Chem Lett; 2013 Sep; 23(18):5140-4. PubMed ID: 23937979
[TBL] [Abstract][Full Text] [Related]
18. Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor.
Jain J; Almquist SJ; Heiser AD; Shlyakhter D; Leon E; Memmott C; Moody CS; Nimmesgern E; Decker C
J Pharmacol Exp Ther; 2002 Sep; 302(3):1272-7. PubMed ID: 12183689
[TBL] [Abstract][Full Text] [Related]
19. Inosine-5'-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation.
Zimmermann AG; Gu JJ; Laliberté J; Mitchell BS
Prog Nucleic Acid Res Mol Biol; 1998; 61():181-209. PubMed ID: 9752721
[TBL] [Abstract][Full Text] [Related]
20. [The determination and clinical application of inosine 5’-monophosphate dehydrogenase activity].
Liu FY; Qiu XY; Jiao Z
Yao Xue Xue Bao; 2016 Nov; 51(11):1666-73. PubMed ID: 29908108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
